Qsymia, Belviq Make Progress With Aetna, But Coverage Remains Long-Term Challenge
Aetna has issued a revised clinical policy bulletin that includes Qsymia and Belviq among the drugs it considers to be “medically necessary weight reduction medications” when a series of criteria are met.
You may also be interested in...
Novo looks to expand indication for its popular diabetes drug, which if approved would go up against competitors that have had trouble on the market.
Company reports several hundred prescribers have completed online training as part of the Risk Evaluation and Mitigation Strategy for the weight loss drug, which is moving toward a fourth-quarter entry into the marketplace.
With a July 17 user fee date, Vivus’ obesity drug Qnexa could beat Arena Pharmaceuticals’ Belviq to the marketplace as lorcaserin awaits controlled substance scheduling by the Drug Enforcement Agency.